natgillin/translations-raw huggingface dataset:
Patienter med lamivudin-resistent kronisk hepatitis B: Der blev ikke identificeret nye bivirkninger af tenofovir disoproxil i et randomiseret, dobbeltblindt studie (GS-US-174-0121), hvor 280 lamivudin-resistente patienter fik tenofovir disoproxil (n = 141) eller emtricitabin/ tenofovir disoproxil (n = 139) i 240 uger. 
Patients with lamivudine-resistant chronic hepatitis B: No new adverse reactions to tenofovir disoproxil were identified from a randomised, double-blind study (GS-US-174-0121) in which 280 lamivudine-resistant patients received treatment with tenofovir disoproxil (n = 141) or emtricitabine/tenofovir disoproxil (n = 139) for 240 weeks.
Da tenofovir disoproxil kan forårsage nyretoksicitet, anbefales tæt monitorering af nyrefunktionen hos voksne patienter med nedsat nyrefunktion, som behandles med Tenofovir disoproxil Mylan (se pkt. 
Since tenofovir disoproxil can cause renal toxicity, close monitoring of renal function is recommended in adult patients with renal impairment treated with Tenofovir disoproxil Mylan (see sections 4.2, 4.4 and 5.2).
Samtidig administration af tenofovir disoproxil og didanosin anbefales ikke, da det kan øge risikoen for bivirkninger (se pkt. 
Co-administration of tenofovir disoproxil and didanosine is not recommended as this may result in an increased risk of adverse reactions (see section 4.5).
96b 144e 192h 240j 288m 384o 96c 144f 
Week b e h j m 384o c f i k n 384p
Tenofovir disoproxil Mylan fås kun som 245 mg filmovertrukne tabletter. 
Tenofovir disoproxil Mylan is available only as 245 mg film-coated tablets.
141 voksne forsøgspersoner blev randomiseret til en behandlingsarm med tenofovir disoproxil, og 139 voksne forsøgspersoner blev randomiseret til en behandlingsarm med emtricitabin plus tenofovir disoproxil. 
One hundred forty-one and 139 adult subjects were randomised to a tenofovir disoproxil and emtricitabine plus tenofovir disoproxil treatment arm, respectively.
Det er vist, at samtidig administration af tenofovir disoproxil og ledipasvir/sofosbuvir, sofosbuvir/velpatasvir eller sofosbuvir/velpatasvir/voxilaprevir øger plasmakoncentrationen af tenofovir, især ved brug af et HIV-regime, der indeholder tenofovir disoproxil og en farmakokinetisk booster (ritonavir eller cobicistat). 
Co-administration of tenofovir disoproxil with ledipasvir/sofosbuvir, sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir has been shown to increase plasma concentrations of tenofovir, especially when used together with an HIV regimen containing tenofovir disoproxil and a pharmacokinetic enhancer (ritonavir or cobicistat).
Erfaring hos patienter med vedvarende viral replikation (studie GS-US-174-0106) Virkningen og sikkerheden af 245 mg tenofovir disoproxil eller 245 mg tenofovir disoproxil sammen med 200 mg emtricitabin er blevet evalueret i et randomiseret dobbelt-blindt studie (studie GS-US-174-0106) med HBeAg-positive og HBeAg-negative voksne patienter, som havde vedvarende viræmi (HBV-dna ≥ 1.000 kopier/ml), mens de fik 10 mg adefovirdipivoxil i mere end 24 uger. 
Experience in patients with persistent viral replication (study GS-US-174-0106) The efficacy and safety of tenofovir disoproxil 245 mg or tenofovir disoproxil 245 mg plus 200 mg emtricitabine has been evaluated in a randomised, double-blind study (study GS-US-174-0106), in HBeAg positive and HBeAg negative adult patients who had persistent viraemia (HBV DNA ≥ 1,000 copies/ml) while receiving adefovir dipivoxil 10 mg for more than 24 weeks.
Sikkerheden af tenofovir disoproxil sammen med ledipasvir/sofosbuvir, sofosbuvir/velpatasvir eller sofosbuvir/velpatasvir/voxilaprevir og en farmakokinetisk booster er ikke klarlagt. 
The safety of tenofovir disoproxil in the setting of ledipasvir/sofosbuvir, sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir and a pharmacokinetic enhancer has not been established.
* p-værdi versus adefovirdipivoxil < 0,05. a Komplet respons defineret som HBV-dna-niveauer < 400 kopier/ml og en forbedring af Knodells nekroinflammatoriske score på mindst 2 points uden forværring af Knodells fibrosescore. 
Complete response defined as HBV DNA levels < 400 copies/ml and Knodell necroinflammatory score improvement of at least 2 points without worsening in Knodell fibrosis.
b Forbedring af Knodells nekroinflammatoriske score på mindst 2 points uden forværring af Knodells fibrosescore. 
Knodell necroinflammatory score improvement of at least 2 points without worsening in Knodell fibrosis.
I studierne GS-US-174-0102 og GS-US-174-0103 skiftede patienterne uden behandlingsafbrydelse til open-label-behandling med tenofovir disoproxil efter at have fået dobbeltblind-behandling i 48 uger (enten 245 mg tenofovir disoproxil eller 10 mg adefovirdipivoxil). 
In studies GS-US-174-0102 and GS-US-174-0103, after receiving double-blind treatment for 48 weeks (either tenofovir disoproxil 245 mg or adefovir dipivoxil 10 mg), patients rolled over with no interruption in treatment to open-label tenofovir disoproxil.
Samtidig administration af tenofovir disoproxil og didanosin resulterer i en 40-60% stigning i systemisk eksponering for didanosin, hvilket kan øge risikoen for didanosinrelaterede bivirkninger. 
Co-administration of tenofovir disoproxil and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk for didanosine-related adverse reactions.
Hver Tenofovir disoproxil Mylan-tablet indeholder 245 mg tenofovir disoproxil (som maleat). 
Each Tenofovir disoproxil Mylan tablet contains 245 mg of tenofovir disoproxil (as maleate).
4.4, 4.8 og 5.1). 
• decompensated liver disease (see sections 4.4, 4.8 and 5.1).
Da det er mere sandsynligt, at ældre patienter har nedsat nyrefunktion, skal der udvises forsigtighed ved behandling af ældre patienter med tenofovir disoproxil (se pkt. 
Elderly patients are more likely to have decreased renal function, therefore caution should be exercised when treating elderly patients with tenofovir disoproxil (see section 4.4).
Hos HIV 1-inficerede børn var BMD Z-scores hos forsøgspersoner, der skiftede til tenofovir disoproxil, lavere end de scores, der blev observeret hos forsøgspersoner, som bibeholdt deres stavudin- eller zidovudin-holdige behandlinger (se pkt. 
In HIV-1 infected children, the BMD Z-scores observed in subjects who switched to tenofovir disoproxil were lower than those observed in subjects who remained on their stavudine- or zidovudine-containing regimen (see sections 4.4 and 5.1).
<til flaskeetiket og pakke> Skal anvendes inden for 90 dage efter første åbning 
<for bottle label and carton> After first opening use within 90 days
Erfaring efter 240 uger hos patienter med lamivudin-resistent HBV (studie GS-US-174-0121) Virkningen og sikkerheden af 245 mg tenofovir disoproxil blev evalueret i et randomiseret, dobbeltblindt studie (GS-US-174-0121) hos HBeAg-positive og HBeAg-negative patienter (n = 280) med kompenseret leversygdom, viræmi (HBV-dna ≥ 1.000 IE/ml) og genotype-evidens for lamivudinresistens (rtM204I/V +/- rtL180M). 
Experience in patients with lamivudine-resistant HBV at 240 weeks (study GS-US-174-0121) The efficacy and safety of 245 mg tenofovir disoproxil was evaluated in a randomised, double-blind study (GS-US-174-0121) in HBeAg positive and HBeAg negative patients (n = 280) with compensated liver disease, viraemia (HBV DNA ≥ 1,000 IU/ml), and genotypic evidence of lamivudine resistance (rtM204I/V +/- rtL180M).
- Tenofovir disoproxil Mylan bør ikke tages samtidigt med adefovirdipivoxil. 
- Tenofovir disoproxil Mylan should not be administered concomitantly with adefovir dipivoxil.
Hvis der er mistanke om nyreabnormiteter, eller disse påvises, skal konsultation med en nefrolog foretages for at overveje at afbryde behandlingen med tenofovir disoproxil. 
If renal abnormalities are suspected or detected then consultation with a nephrologist should be obtained to consider interruption of tenofovir disoproxil treatment.
Hver filmovertrukket tablet indeholder 245 mg tenofovir disoproxil (som maleat). 
Each film-coated tablet contains 245 mg of tenofovir disoproxil (as maleate).
HBV-dna (%) < 400 kopier/ml (< 69 IE/ml) ALAT (%) Normaliseret ALATd 
HBV DNA (%) < 400 copies/ml (< 69 IU/ml) ALT (%) Normalised ALT
426 HBeAg-negative (GS-US-174-0102, n = 250) og HBeAg-positive (GS-US-174-0103, n = 176) patienter, der initialt blev randomiseret til behandling med dobbelt-blind tenofovir disoproxil og derefter skiftede til open-label-behandling med tenofovir disoproxil, blev undersøgt for genotypeændringer i HBV-polymerase i forhold til baseline. 
Four hundred and twenty-six HBeAg negative (GS-US-174-0102, n = 250) and HBeAg positive (GS-US-174-0103, n = 176) patients initially randomised to double-blind tenofovir disoproxil treatment and then switched to open-label tenofovir disoproxil treatment were evaluated for genotypic changes in HBV polymerase from baseline.
Behandlingen bør ikke seponeres hos patienter med fremskreden leversygdom eller levercirrose, da eksacerbationer efter behandlingen kan føre til hepatisk dekompensation. 
In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.
215 HBeAg-negative (GS-US-174-0102, n = 125) og HBeAg-positive (GS-US-174-0103, n = 90) patienter, der initialt blev randomiseret til behandling med dobbelt-blind adefovirdipivoxil og derefter skiftede til open-label-behandling med tenofovir disoproxil, blev undersøgt for genotype-ændringer i HBV-polymerase i forhold til baseline. 
Two hundred and fifteen HBeAg negative (GS-US-174-0102, n = 125) and HBeAg positive (GS-US174-0103, n = 90) patients initially randomised to double-blind adefovir dipivoxil treatment and then switched to open-label tenofovir disoproxil treatment were evaluated for genotypic changes in HBV polymerase from baseline.
HBV-stammer med rtA181Vog rtN236T-mutationer med relation til adefovirresistens udviste en følsomhed over for tenofovir fra 2,9 til 10 gange den for vildtypevirus. 
HBV strains expressing the adefovir-associated resistance mutations rtA181V and rtN236T showed a susceptibility to tenofovir ranging from 2.9- to 10-fold that of wild-type virus.
Kronisk hepatitis B: Hos unge i alderen 12 til < 18 år, der vejer ≥ 35 kg er den anbefalede dosis af tenofovir disoproxil 245 mg (én tablet) en gang dagligt taget oralt sammen med mad (se pkt. 
Chronic hepatitis B: In adolescents aged 12 to < 18 years and weighing ≥ 35 kg, the recommended dose of tenofovir disoproxil is 245 mg (one tablet) once daily, taken orally with food (see sections 4.8 and 5.1).
ETIKETTERING PÅ FLASKEKARTON OG FLASKE 
BOTTLE CARTON AND BOTTLE LABEL
Tenofovir disoproxol Mylan 245 mg filmovertrukne tabletter indeholder lactosemonohydrat. 
Tenofovir disoproxil Mylan 245 mg film-coated tablets contain lactose monohydrate.
Anvendelsen af tenofovir disoproxil anbefales ikke til pædiatriske patienter med nedsat nyrefunktion (se pkt. 
The use of tenofovir disoproxil is not recommended in paediatric patients with renal impairment (see section 4.2).
+ Raltegravir (400 mg b.i.d) + Emtricitabin/Tenofovir disoproxil (200 mg/245 mg q.d.) 
+ Raltegravir (400 mg b.i.d) + Emtricitabine/Tenofovir disoproxil (200 mg/245 mg q.d.)
Samtidig administration af sofosbuvir/velpatasvir og efavirenzindeholdende regimer frarådes. 
Coadministration of sofosbuvir/velpatasvir with efavirenzcontaining regimens is not recommended.
• Laktatacidose (overskud af mælkesyre i blodet) er en sjælden (kan opstå hos op til 1 ud af 
• Lactic acidosis (excess lactic acid in the blood) is a rare (can affect up to 1 in every 1,000 patients) but serious side effect that can be fatal.
Demografien ved baseline var sammenlignelig for de to behandlingsarme: ved baseline var 52,5% af forsøgspersonerne HBeAg-negative, 47,5% var 
Baseline demographics were similar between the two treatment arms: At baseline, 52.5% of subjects were HBeAg negative, 47.5% were HBeAg positive, mean HBV DNA level was 6.5 log10 copies/ml, and mean ALT was 79 U/l, respectively.
Tenofovir disoproxil bør ikke tages samtidigt med adefovirdipivoxil. 
Tenofovir disoproxil should not be administered concomitantly with adefovir dipivoxil.
Tag ikke Tenofovir disoproxil Mylan 
Do not take Tenofovir disoproxil Mylan:
BMD Z-scores blev ikke justeret for højde og vægt b 
NA = Not Applicable a BMD Z-scores not adjusted for height and weight b Primary safety endpoint through week 72
BMD Z-scores, der blev observeret hos forsøgspersoner, som fik tenofovir disoproxil, var lavere end de scores, der blev observeret hos forsøgspersoner, som fik placebo (se pkt. 
The BMD Z-scores observed in subjects who received tenofovir disoproxil were lower than those observed in subjects who received placebo (see sections 4.4 and 5.1).
Prøver kan også vise: • problemer med lever 
Tests may also show: • decreases in phosphate in the blood
l De viste tal er kumulative procenter baseret på en Kaplan Meier-analyse, som ekskluderer data indsamlet efter tillæg af emtricitabin til open-label tenofovir disoproxil (KM-tenofovir disoproxil). 
Figures presented are cumulative percentages based upon a Kaplan Meier analysis excluding data collected after the addition of emtricitabine to open-label tenofovir disoproxil (KM-tenofovir disoproxil).
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE OG DEN INDRE EMBALLAGE 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND IMMEDIATE PACKAGING
g De viste tal er kumulative procentdele baseret på en Kaplan Meier-analyse, som inkluderer data indsamlet efter tillæg af emtricitabin til open-label tenofovir disoproxil (KM-ITT). 
Figures presented are cumulative percentages based upon a Kaplan Meier analysis including data collected after the addition of emtricitabine to open-label tenofovir disoproxil (KM-ITT).
Ved behandlingsintentionsanalyse (manglende data og skift i antiretroviral behandling (ART) blev betragtet som svigt) var procentdelen af patienter med HIV 1-rna under 400 kopier/ml og 50 kopier/ml i uge 48 af behandlingen henholdsvis 80% og 76% i 245 mg tenofovir disoproxil behandlingsarmen, sammenlignet med 84% og 80% i stavudin behandlingsarmen. 
By intent to treat analysis (missing data and switch in antiretroviral therapy (ART) considered as failure), the proportion of patients with HIV-1 RNA below 400 copies/ml and 50 copies/ml at 48 weeks of treatment was 80% and 76% respectively in the tenofovir disoproxil 245 mg arm, compared to 84% and 80% in the stavudine arm. At 144 weeks, the proportion of patients with HIV-1 RNA below 400 copies/ml and 50 copies/ml was 71% and 68% respectively in the tenofovir disoproxil 245 mg arm, compared to 64% and 63% in the stavudine arm.
Følgende bivirkninger er sjældne (kan opstå hos op til 1 ud af 1.000 personer): 
The following side effects are rare (these can affect up to 1 in every 1,000 patients):
Til de mange risikofaktorer for udvikling af denne sygdom hører blandt andre: Varigheden af kombinationsbehandlingen, anvendelse af kortikosteroider, alkoholforbrug, alvorligt nedsat immunforsvar, samt (over-)vægt (højere Body Mass Index (BMI)). 
The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index, among others, may be some of the many risk factors for developing this disease.
Ætiologien anses dog for at være multifaktoriel (omfattende anvendelse af kortikosteroider, alkoholforbrug, svær immunosuppression, højere Body Mass Index (BMI)). 
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported, particularly in patients with advanced HIV disease and/or long-term exposure to CART.
Tenofovir disoproxil Mylan 245 mg filmovertrukne tabletter tenofovir disoproxil 
Tenofovir disoproxil Mylan 245 mg film-coated tablets tenofovir disoproxil
Reduktion på mindst 6% i BMD for columna lumbalisb 
Lumbar spine BMD at least 6% decrease b NA
Hos patienter i behandling med tenofovir disoproxil med risikofaktorer for renal dysfunktion er der blevet rapporteret tilfælde af akut nyresvigt efter påbegyndelse af højdosisbehandling med nonsteroide antiinflammatoriske midler (NSAID'er) og behandling med flere NSAID'er. 
Cases of acute renal failure after initiation of high dose or multiple non-steroidal anti-inflammatory drugs (NSAIDs) have been reported in patients treated with tenofovir disoproxil and with risk factors for renal dysfunction.
Data for knoglemineraltæthed (BMD) fra studie GS-US-174-0115 er opsummeret i tabel 8: 
Bone Mineral Density (BMD) data from Study GS-US-174-0115 are summarized in Table 8: Table 8: Bone Mineral Density Evaluation at Baseline, Week 72 and 192
Samtidig administration af af tenofovir disoproxil og didanosin resulterer i en 40-60% stigning i systemisk eksponering for didanosin, hvilket kan øge risikoen for didanosin-relaterede bivirkninger (se pkt. 
Co-administration of tenofovir disoproxil and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Den forøgede tenofovir-eksponering kan medføre forstærkede bivirkninger af tenofovir disoproxil, herunder nyrerelaterede bivirkninger. 
The increased exposure of tenofovir could potentiate adverse reactions associated with tenofovir disoproxil, including renal disorders.
200 mg emtricitabin/ 245 mg tenofovir disoproxil (n = 45) 
Emtricitabine 200 mg/ tenofovir disoproxil 245 mg (n = 45)
De observerede bivirkninger hos pædiatriske patienter, der fik behandling med tenofovir disoproxil var overensstemmende med dem, der blev observeret i kliniske studier af tenofovir disoproxil hos voksne (se pkt. 
The adverse reactions observed in paediatric patients who received treatment with tenofovir disoproxil were consistent with those observed in clinical studies of tenofovir disoproxil in adults (see section 4.8 Tabulated summary of adverse reactions and 5.1).
Knogler, led, muskler og bindevæv: Ikke almindelig: 
angioedema Musculoskeletal and connective tissue disorders: Uncommon:
Der blev udført genotypestudier på alle patienter i denne gruppe med HBV-dna > 400 kopier/ml ved uge 96 (n = 17), uge 144 (n = 7) og uge 192 (n = 8). 
Genotypic evaluations were performed on all patients within this group with HBV DNA > 400 copies/ml at week 96 (n = 17),
Fås i følgende pakningsstørrelser:30 filmovertrukne tabletter og multipakninger med 90 filmovertrukne tabletter (3 pakker af 30). 
This medicine is available in plastic bottles with a child resistant cap and wad containing 30 filmcoated tablets and in multipacks of 90 film-coated tablets comprising 3 bottles, each containing 30 film-coated tablets.
Hvis De har særlige problemer med at synke, kan De knuse tabletten med spidsen af en ske og opløse den i ca. 100 ml (et halvt glas) vand, appelsinjuice eller druesaft. 
Then mix the powder with about 100 ml (half a glass) of water, orange juice or grape juice and drink immediately
Samtidig administration af tenofovir disoproxil og didanosin anbefales ikke, da det resulterer i en stigning i systemisk eksponering for didanosin på 40-60%, hvilket kan øge risikoen for didanosinrelaterede bivirkninger (se pkt. 
Co-administration of tenofovir disoproxil and didanosine is not recommended as it results in a 4060% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Gennemsnitlig (SD) BMD Zscore for hele kroppena 
Whole body mean (SD) BMD Z-score a
Sådan skal De tage Tenofovir disoproxil Mylan 
How to take Tenofovir disoproxil Mylan
Dette er baseret på modellering af farmakokinetiske data for enkeltdosis hos HIV-negative patienter eller patienter uden HBV-infektion men med forskellige grader af nedsat nyrefunktion, herunder nyresygdom i slutstadiet, hvor det er nødvendigt med dialyse, og er ikke blevet bekræftet i kliniske studier. 
Administration of 245 mg tenofovir disoproxil every 48 hours can be used based on modelling of single-dose pharmacokinetic data in HIV negative and non-HBV infected subjects with varying degrees of renal impairment, including end-stage renal disease requiring haemodialysis, but has not been confirmed in clinical studies.
Til flasker: Skal anvendes inden for 90 dage efter første åbning. 
For bottles: after first opening the bottle use within 90 days.
245 mg tenofovir disoproxil n = 176 
Tenofovir disoproxil 245 mg n = 176
OPLYSNINGER, DER SKAL ANFØRES PÅ YDEREMBALLAGEN 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Følgende bivirkninger er meget almindelige (kan opstå hos mere end 10 ud af 100 personer): 
The following side effects are common (these can affect up to 10 in every 100 patients):
e 48 uger dobbeltblind tenofovir disoproxil, efterfulgt af 96 uger open-label. 
e 48 weeks of double-blind tenofovir disoproxil followed by 96 weeks open-label.
Tenofo vir disopro xiltenofovi r disopro xil 
HBeAg loss/ seroconversion HBsAg loss/ seroconversion g g l l g g l l a
Tenofovir disoproxil Mylan 245 mg filmovertrukne tabletter 
Tenofovir disoproxil Mylan 245 mg film-coated tablets
Kør ikke bil eller motorcykel, lad være med at cykle og lad være med at arbejde med værktøj eller maskiner, hvis De bliver svimmel, når De tager Tenofovir disoproxil Mylan. 
If you feel dizzy while taking Tenofovir disoproxil Mylan, do not drive or ride a bicycle and do not use any tools or machines.
Opbevaring af Tenofovir disoproxil Mylan 
How to store Tenofovir disoproxil Mylan
Samtidig administration af tenofovir disoproxil og didanosin kan ikke anbefales (se pkt. 
Co-administration of tenofovir disoproxil and didanosine is not recommended (see section 4.4).
Lactosemonohydrat 
rhabdomyolysis
De observerede bivirkninger hos unge patienter, som blev behandlet med tenofovir disoproxil, svarede til de bivirkninger, der blev observeret i kliniske studier af tenofovir disoproxil hos voksne (se pkt. 
The adverse reactions observed in adolescent patients who received treatment with tenofovir disoproxil were consistent with those observed in clinical studies of tenofovir disoproxil in adults (see section 4.8 Tabulated summary of adverse reactions and 5.1).
Almene symptomer og reaktioner på administrationssstedet: Meget almindelig: asteni 
2, nephrogenic diabetes insipidus General disorders and administration site conditions: Very common:
245 mg tenofovir disoproxil (n = 45) 
Tenofovir disoproxil 245 mg (n = 45)
b 48 uger dobbeltblind tenofovir disoproxil, efterfulgt af 48 uger open-label. 
b 48 weeks of double-blind tenofovir disoproxil followed by 48 weeks open-label.
Overtræk 
dizziness
Sikkerheden af tenofovir disoproxil sammen med ledipasvir/sofosbuvir og en farmakokinetisk booster (f.eks. ritonavir eller cobicistat) er ikke klarlagt. 
The safety of tenofovir disoproxil when used with ledipasvir/sofosbuvir and a pharmacokinetic enhancer (e.g. ritonavir or cobicistat) has not been established.
Det skal De vide, før De begynder at tage Tenofovir disoproxil Mylan Sådan skal De tage Tenofovir disoproxil Mylan Bivirkninger 
What Tenofovir disoproxil Mylan is and what it is used for What you need to know before you take Tenofovir disoproxil Mylan How to take Tenofovir disoproxil Mylan Possible side effects
p 48 uger dobbeltblind adefovirdipivoxil, efterfulgt af 336 uger open-label tenofovir disoproxil. 
p 48 weeks of double-blind adefovir dipivoxil followed by 336 weeks open-label tenofovir disoproxil.
Følgende bivirkninger er ikke almindelige (kan opstå hos op til 1 ud af 100 personer): 
The following side effects are uncommon (these can affect up to 1 in every 100 patients):
Den forøgede tenofovir-eksponering kan forstærke effekten af bivirkninger ved tenofovir, herunder nyresygdomme. 
The increased exposure of tenofovir could potentiate tenofovirassociated adverse events, including renal disorders.
o 48 uger dobbeltblind tenofovir disoproxil, efterfulgt af 336 uger open-label. 
o 48 weeks of double-blind tenofovir disoproxil followed by 336 weeks open-label.
osteomalaci (manifesterer sig som knoglesmerter og i sjældne tilfælde medvirkende årsag til frakturer) 
osteomalacia (manifested as bone pain and infrequently contributing to fractures) , myopathy Renal and urinary disorders: Uncommon: